Getinge AB GETI B

STO: GETI B | ISIN: SE0000202624 25/04/2025

184,45 SEK (+1,10%)

(+1,10%) 25/04/2025

Toon enkel gratis nieuws

22 april 2025 · Getinge Interim Report January-March 2025: Strong sales and improved earnings - continued focus on customer value and profitability going forward · Persbericht

27 maart 2025 · Getinge publishes Annual Report for 2024 · Persbericht

11 september 2024 · Getinge completes the acquisition of Paragonix Technologies · Persbericht

22 augustus 2024 · Getinge to acquire Paragonix Technologies, a growth leader in the organ transplantation market · Persbericht

18 juli 2024 · Getinge Interim Report April-June 2024: Higher sales, stronger margins and product launches with significant added value for customers · Persbericht

14 mei 2024 · Getinge's financial target 2024-2028: Adjusted EPS growth of above 12% on average · Persbericht

8 maart 2024 · Getinge takes a leap forward in cardiovascular surgery with the 510(k) clearance for Vasoview Hemopro 3 · Persbericht

11 oktober 2023 · Getinge acquires Healthmark Industries Co. Inc. · Persbericht

7 juli 2023 · Getinge recieves US FDA 510(k) clearance for Servo-air® Lite · Persbericht

31 mei 2023 · Getinge to acquire High Purity New England, Inc., a leading provider of single-use solutions for bioprocessing applications · Persbericht

24 maart 2023 · Getinge recieves FDA premarket approval for the iCast™ covered stent system in the US · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe